CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancerMalachi Griffith, Obi L. Griffith, Adam Coffman et al.|Nature Genetics|2017Cited by 673
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast CancerX. Cynthia, Matthew J. Ellis, Vera J. Suman et al.|Clinical Cancer Research|2017Cited by 74